1. HBW Insight
  2. >>Health
  3. >>Business
  4. >>Deals

Takeda Offloads Emerging Market OTCs to Acino

 
• By Tom Gallen

Takeda is shedding some unwanted OTC assets in a number of emerging markets as part of its efforts to pay down debt and focus its portfolio following its acquisition of Shire. 

Takeda
• Source: Shutterstock

Japan’s Takeda Pharmaceutical Co. Ltd. is set to divest a portfolio of OTC and prescription drugs marketed mainly across the Middle East and Africa to Switzerland-based Acino Holding AG.

With the deal valued at upwards of $200m, Takeda said the move would help pay down debt following its acquisition...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Reckitt Strikes Deal To Sell Essential Home Unit To Focus On CHC, Hygiene

 
• By Tom Gallen

Advent International is poised to take control of Reckitt's Essential Home business, but the UK-based firm will retain a 30% stake.

Perrigo Implements Streamlining Plan With Sale Of Dermacosmetics

 
• By Tom Gallen

Perrigo stands to gain up to €327m with sale of brands such as ACO and Emolium to KKR.

Haleon Takes Full Control Of China JV

 
• By Tom Gallen

Haleon finalizes deal to make its China joint venture a wholly-owned subsidiary in move to "drive category growth in one of the fastest growing OTC markets globally."

Navamedic Adds OTC Naloxone With DNE Pharma Acquisition

 
• By Tom Gallen

Norway's Navamedic will move into the addiction treatment market with the acquisition of DNE Pharma, adding to its portfolio an OTC opioid overdose reversal spray.

More from Business

Private Label ‘Smart Imitation’ Of National Brands’ Packaging Not So Wise In US OTC Drug Sector

 
• By Malcolm Spicer

First Insight survey with 1,267 US consumers showed 44% are more likely to try a private label product “marketed as a dupe of a high-end product.” Providers of OTC drugs as well as other medical products in US would tread on thin regulatory ice with the practice.

Haleon Invests In State-Of-The-Art Oral Care R&D Facility In The UK

 
• By David Ridley

Haleon described the opening of a new oral care R&D facility in the UK as a “major investment reflecting our commitment to advancing science and innovation.”

Over The Counter: How To Balance Access And Equity In Self-Care, With Bayer’s Emese Csoke

HBW Insight speaks to Bayer Consumer Health's global strategy director for regulatory, medical, safety, quality, and compliance Emese Csoke about how least how widening access to self-care solutions can be balanced with equity with regards to affordability.